Vaccines

A new 31-strain vaccine enters final trials, threatening to upend the market and offer unprecedented protection against a persistent bacterial threat.

With promising clinical data and a streamlined FDA path, a smarter molecule could finally offer a better, more tolerable treatment for idiopathic pulmonary fibrosis.

New data shows Ascentage Pharma's drug achieves responses where a leading therapy fails, signaling a strategic coup in the high-stakes oncology market.

A class action lawsuit against Telix Pharmaceuticals reveals the perilous gap between optimistic corporate disclosures and harsh regulatory setbacks.

The PAS 2026 meeting is more than a conference; it's a convergence of science, capital, and community, signaling major shifts in pediatric care.